Traws Pharma, Inc.
TRAW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001130598
No open-market purchases or sales by Traws Pharma, Inc. insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $5.19M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Traws Pharma, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +7 vs. Q3 2024
- Shares held
- 1.17M
- +524.0K (+81.1%) vs. Q3 2024
- Total value
- $10.2M
- +$6.45M (+169.7%) vs. Q3 2024
- New holders
- 9
- 3 more added
- Sold out
- 2
- 2 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TRAW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 34 | $5.19M |
| Q1 2026 | 28 | $6.62M |
| Q4 2025 | 22 | $3.86M |
| Q3 2025 | 18 | $2.41M |
| Q2 2025 | 19 | $1.87M |
| Q1 2025 | 19 | $3.98M |
| Q4 2024 | 19 | $10.2M |
| Q3 2024 | 12 | $3.80M |
| Q2 2024 | 30 | $1.36M |
| Q1 2024 | 26 | $1.88M |
| Q4 2023 | 27 | $1.35M |
| Q3 2023 | 28 | $1.27M |
| Q2 2023 | 24 | $2.19M |
| Q1 2023 | 25 | $1.04M |
| Q4 2022 | 29 | $1.01M |
| Q3 2022 | 30 | $1.54M |
| Q2 2022 | 32 | $2.36M |
| Q1 2022 | 28 | $3.60M |
| Q4 2021 | 34 | $6.14M |
| Q3 2021 | 37 | $10.5M |
| Q2 2021 | 24 | $10.9M |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Traws Pharma, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cornerstone Planning Group LLC | 1 | $7 | 0.00% | 00.0% | Unchanged |
| Pacific Capital Wealth Advisors, Inc | 2 | $18 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 76 | $675 | 0.00% | −2,062−96.4% | Reduced |
| SBI Securities Co., Ltd. | 155 | $1.38K | 0.00% | +155 | New |
| Vermillion & White Wealth Management Group, LLC | 205 | $1.82K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 791 | $7.02K | 0.00% | +161+25.6% | Added |
| Group One Trading, L.P. | 1,164 | $10.3K | 0.00% | +1,100+1,718.8% | Added |
| BlackRock, Inc. | 9,956 | $88.4K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 10,012 | $88.9K | 0.00% | +10,012 | New |
| Renaissance Technologies LLC | 10,052 | $89.3K | 0.00% | +10,052 | New |
| Boothbay Fund Management, LLC | 28,431 | $108.2K | 0.00% | +28,431 | New |
| Vanguard Group Inc | 13,141 | $116.7K | 0.00% | −13,581−50.8% | Reduced |
| Morgan Stanley | 15,725 | $139.6K | 0.00% | +14,996+2,057.1% | Added |
| Geode Capital Management, LLC | 20,801 | $184.7K | 0.00% | +20,801 | New |
| Vestal Point Capital, LP | 75,000 | $666.0K | 0.04% | +75,000 | New |
| Ikarian Capital, LLC | 98,493 | $874.6K | 0.25% | +98,493 | New |
| Alyeska Investment Group, L.P. | 116,714 | $1.04M | 0.00% | +116,714 | New |
| Perceptive Advisors LLC | 164,157 | $1.46M | 0.04% | +164,157 | New |
| OrbiMed Advisors LLC | 605,531 | $5.38M | 0.11% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −379−100.0% | Sold out |
| Danske Bank A/S | 0 | $0 | 0.00% | −7−100.0% | Sold out |